This Biotech Stock Could Soar on Upcoming Clinical Data

Key Points

• Viking's dual-pathway GLP-1/GIP approach with both injectable and oral delivery options could differentiate it in the crowded obesity drug market.

• The company's Phase 2 oral VK2735 readout, expected in the coming weeks, represents a major catalyst that could validate the platform's commercial potential.

• Major pharmaceutical companies facing patent cliffs and pipeline gaps may view Viking as an attractive acquisition target if clinical data proves successful.

• 10 stocks we like better than Viking Therapeutics ›

While most investors pile into Eli Lilly (NYSE: LLY) or flee from struggling Novo Nordisk (NYSE: NVO), they're missing a compelling opportunity in the clinical-stage space. Novo recently lost nearly $70 billion in market cap after cutting 2025 guidance and warning of slowing Wegovy momentum, while the broader biotech industry's recent reawakening has created pockets of value among companies with differentiated approaches to weight management.

Viking Therapeutics (NASDAQ: VKTX) represents exactly this type of overlooked opportunity, trading at a valuation of just $3.7 billion as of Aug. 1, despite owning one of the most strategically valuable obesity platforms in development. Here's what investors need to know right now.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Image source: Getty Images.

A critical catalyst approaches

The investment thesis for Viking centers on an imminent inflection point. The company is expected to report Phase 2 data for its oral VK2735 candidate in the second half of 2025, with September appearing most likely based on trial timelines and enrollment trends.

Viking has already demonstrated that its dual GLP-1/GIP mechanism can drive substantial weight loss, with the highest dose of injectable VK2735 producing up to 14.7% body weight reduction over 13 weeks and 88% of patients achieving at least 10% weight loss. The safety profile was favorable, with most adverse events classified as mild to moderate and primarily gastrointestinal.

The upcoming oral data will test whether this level of efficacy and tolerability can be achieved in a more convenient, patient-friendly form. Success would mark a major step forward in oral obesity drug development and significantly strengthen Viking's strategic position.

Competitive landscape creates opportunity

The obesity drug market's competitive dynamics are shifting in Viking's favor. Pfizer (NYSE: PFE) recently abandoned its lead GLP-1 program after encountering severe gastrointestinal side effects.Roche spent $2.7 billion acquiring Carmot Therapeutics, only to see key candidates fail in clinical trials. Even market leader Novo Nordisk faces mounting pressure from generic semaglutide compounds and continues to struggle with a credible oral successor to Wegovy.

These setbacks have created a wide-open competitive lane for Viking's differentiated approach, potentially offering superior efficacy and fewer side effects compared to single-pathway competitors. The dual-receptor mechanism also underpins the strong clinical results already seen with the injectable version in earlier trials.

Viking's strategic positioning becomes even more compelling when considering the broader market dynamics. The obesity drug market is projected to reach $100 billion in annual sales by 2030, yet few companies have successfully advanced oral alternatives through clinical development. This scarcity premium could drive significant strategic interest if Viking's oral data support a best-in-class profile.

Multiple value creation pathways

Viking's investment appeal extends beyond binary clinical success. The company offers multiple pathways to value creation, starting with potential strategic partnerships or acquisition interest. Major pharmaceutical companies, including Pfizer, Merck, and Bristol Myers Squibb, face significant patent cliff challenges over the coming years, creating urgent demand for new revenue drivers.

Viking's unpartnered status, clean intellectual property position, and manageable valuation make it an attractive target for companies seeking to plug obesity drug portfolio gaps. The timing appears particularly favorable given the limited number of advanced oral GLP-1 assets available for acquisition.

Alternatively, Viking could pursue independent commercialization through innovative partnership models. The rise of direct-to-consumer healthcare platforms such as Hims & Hers demonstrates growing market acceptance of subscription-based treatment models. An oral maintenance therapy could integrate seamlessly into such platforms, potentially creating recurring revenue streams with attractive margins.

Even Novo Nordisk, despite its top-two position in the market, could emerge as a strategic suitor. The company recently cut 2025 guidance and warned of slowing Wegovy momentum, while facing new leadership under CEO Maziar Doustdar. Acquiring Viking's differentiated platform could provide instant credibility and critical pipeline reinforcement.

Risks remain significant but manageable

As with all clinical-stage biotechnology investments, Viking carries substantial execution risk. The oral formulation may not mirror the injectable version's efficacy all that closely, potentially limiting commercial appeal. Moreover, regulatory pathways for obesity drugs continue evolving, and manufacturing scale-up presents additional challenges.

Competition from established players also poses ongoing threats. Eli Lilly's Zepbound continues gaining market share, while other companies advance competing oral formulations. Viking's ultimate success depends on demonstrating clear differentiation rather than simply achieving clinical efficacy.

However, these risks appear manageable given Viking's competitive injectable data, combined with the strategic value of dual-modality approaches. The company's experienced management team and sufficient cash runway provide additional downside protection.

The readout determines everything

Viking Therapeutics offers a compelling risk-reward proposition heading into what could be a transformative clinical readout. The company's dual-pathway approach addresses validated market needs, while competitive setbacks have created strategic scarcity in oral obesity drug development.

Success with the oral VK2735 data could trigger multiple value creation scenarios, from strategic acquisition at substantial premiums to licensing partnerships that unlock recurring revenue models. Even independent development remains a viable path, given the massive market opportunity and limited competition.

For investors willing to accept clinical-stage biotech risk, Viking's current valuation appears attractive relative to the potential outcomes. The forthcoming readout will ultimately determine whether this thesis proves correct, but the setup suggests favorable risk-adjusted returns for those positioned ahead of the catalyst.

Should you invest $1,000 in Viking Therapeutics right now?

Before you buy stock in Viking Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,064,820!*

Now, it’s worth noting Stock Advisor’s total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of July 29, 2025

George Budwell has positions in Pfizer and Viking Therapeutics and has the following options: long January 2026 $55 calls on Viking Therapeutics, long January 2026 $60 calls on Viking Therapeutics, and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends Bristol Myers Squibb, Hims & Hers Health, Merck, and Pfizer. The Motley Fool recommends Novo Nordisk, Roche Holding AG, and Viking Therapeutics. The Motley Fool has a disclosure policy.